Charles River Laboratories has finalized the acquisition of WIL Research from a shareholder group led by American Capital, Ltd. and The Wicks Group. The strategic rationale for this transaction centers on a "service-continuum" play, merging the target's technical operational depth in specialty safety assessment and CDMO services with the group's established global contract research infrastructure. This fusion effectively creates a specialized powerhouse in the early-stage CRO market, providing the organization with the scientific talent required to manage complex R&D requirements for pharmaceutical and industrial chemical clients. This operation allows Charles River Laboratories to enhance its competitive positioning by adding niche toxicological expertise that is critical for regulatory validation. By integrating the target’s specialized technical assets, the group can now provide a more robust and integrated solution set for high-stakes safety assessment, facilitating faster and more certain decision-making for its global customer base. The maneuver optimizes the group's financial profile by adding high-margin, specialized revenue streams from non-discretionary research sectors. Ultimately, the partnership solidifies the organization’s standing as a primary enabler of biopharmaceutical innovation, while ensuring the group remains a highly focused and agile market leader in the drug development lifecycle.

WIL RESEARCH, which reported an EBITDA margin of LOGIN in 2015, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a level LOGIN the 12.8x average currently observed in the Healthcare & Pharma sector.

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.